Further, osteocalcin has been observed to be high in cortical bone in comparison to trabecular bone [35, 36].
This could have been due to very strong expression of sclerostin in the unloaded bone, in comparison to normally-loaded bone, in which case the amount of antibody administered may have been inadequate to fully inhibit sclerostin.
The decrease of retention in bone using the HMGU model consequently reduces the radiation dose estimate in bone in comparison to the ICRP bone dose which is currently used in monitoring.
Epiphyseal bone healing improved in all the osteochondral defects regardless of treatment, although PEMFs alone did not significantly improve the reconstruction of subchondral bone in comparison to treatment with scaffold alone.
The new fixation method invented by Rogala [ 23– 25] and the MSC-Scaffold preprototype designed in our research team [ 27, 28] assumes more physiological load transmission in peri-implant bone in comparison to the traditional short-stem cemented RHA endoprostheses.
Both types of cells, MSC and EPC, demonstrated a significantly decreased adherence on bovine cancellous bone in comparison to β-TCP and processed mineralized human cancellous chips [ 23, 24].
A marked lower initial adherence was observed on bovine cancellous bone in comparison to β-TCP and DBM, whereas adhesion on β-TCP and DBM was at a comparable, high level).
Interestingly, since ZOL, with its high affinity to hydroxyapatite, is concentrated on the bone surface, its effect could be more important than that induced by other Cox-2 inhibitors, which although reducing breast-cancer metastasis, have a reduced affinity for bone in comparison to ZOL (Kundu and Fulton, 2002).
In addition, we found a significantly higher polyethylene wear rate in type III femoral bone loss in comparison to bone defects of type I and II (Mann-Whitney U test; p = 0.007 and p = 0.015 for linear and volumetric wear rate, respectively).
